9 Things to Know About Lichen Sclerosus and Menopause Before Your Doctor Dismisses It
The number of women who've spent years being handed lubricant samples while quietly living with itching, tearing, and architectural changes to their vulva — that number is not small. Lichen sclerosus gets lost in the noise of menopause, and that invisibility has real consequences. If something feels wrong down there and the standard answers aren't helping, this is worth pushing for.
Learn more about Rose →Lichen Sclerosus Is an Autoimmune Condition, Not Just Dryness
Lichen sclerosus (LS) is a chronic inflammatory skin condition driven by immune dysregulation, most commonly affecting the vulvar and perianal skin. Unlike GSM (genitourinary syndrome of menopause), which is caused by falling oestrogen reducing tissue moisture and elasticity, LS involves the immune system attacking the skin itself, causing a distinct pattern of inflammation and scarring. The two conditions can coexist, which is part of why LS so often gets missed — but they have different mechanisms and require different treatment approaches.
Menopause Does Not Cause Lichen Sclerosus, But It Can Unmask It
LS can occur at any age, but there is a well-documented peak in postmenopausal women, with prevalence estimates ranging from 1 in 30 to 1 in 80 women over 50 — figures that are almost certainly underestimates given how rarely it is formally diagnosed. The hormonal shifts of perimenopause may lower the skin's resilience and reduce its ability to contain existing immune activity, allowing a subclinical condition to become symptomatic. This timing is exactly what causes it to be misread as simple hormonal change rather than investigated as its own condition.
The Symptoms Go Beyond Itching and Are Often Described Poorly to Doctors
Classic LS symptoms include intense vulvar itching — often worse at night — along with burning, soreness, skin fragility, tearing during intercourse, and the appearance of white, thickened, or parchment-like patches on the vulvar skin. Over time, structural changes can occur: the labia minora may shrink or fuse, the clitoral hood can adhere, and the vaginal opening may narrow — a process called architectural distortion. Women frequently describe these symptoms in vague terms like 'dryness' or 'sensitivity' because they have no framework for what they are seeing and feeling, making it easy for consultations to be cut short.
Diagnosis Requires Visual Examination — and Sometimes a Biopsy
LS is primarily a clinical diagnosis, meaning a trained clinician should be able to identify it from a careful visual examination of the vulvar skin, though biopsy is recommended when the diagnosis is uncertain, when first-line treatment fails, or when there are atypical features. The problem is that many GP and even gynaecology appointments do not include a proper vulvar examination — women are often asked about symptoms without anyone actually looking. Asking explicitly for a vulvar skin assessment, and if necessary a referral to a vulval dermatology or specialist gynaecology clinic, is a reasonable and well-evidenced next step.
The First-Line Treatment Is a Potent Topical Steroid — Not a Moisturiser
The evidence-based first-line treatment for vulvar LS is a high-potency topical corticosteroid, typically clobetasol propionate 0.05%, applied to the affected skin on a structured reducing regimen over several months. This is not interchangeable with emollients, vaginal oestrogen, or over-the-counter hydrocortisone, which are far too weak to address the underlying inflammation. Women are sometimes told to 'keep the area moisturised' without ever receiving a steroid prescription — a missed opportunity that allows the condition to progress and cause more permanent structural changes.
Vaginal Oestrogen Can Help But Is Not a Substitute for Steroid Treatment
Local oestrogen therapy — in the form of creams, rings, or pessaries — is highly effective for treating the GSM symptoms that may coexist with LS, including vaginal dryness, urinary urgency, and discomfort with penetration caused by tissue atrophy. However, oestrogen does not treat the autoimmune inflammation of LS itself, and women who have both conditions need both treatments addressed. Using oestrogen alone when LS is present may improve some symptoms while allowing the inflammatory scarring process to continue unchecked.
Untreated Lichen Sclerosus Carries a Small But Real Cancer Risk
Women with vulvar LS have an estimated 4–6% lifetime risk of developing vulvar squamous cell carcinoma — a meaningful elevation above background risk, and one that makes long-term monitoring genuinely important rather than precautionary. This risk is substantially reduced with good disease control through appropriate steroid treatment, which is one of the strongest arguments for getting a proper diagnosis and sticking with treatment even when symptoms improve. Any new lesion, persistent ulcer, or area of unusual thickening within LS-affected skin warrants prompt assessment.
Long-Term Steroid Use on Vulvar Skin Is Safer Than Most Women Expect
Many women — and some clinicians — are cautious about applying a potent steroid to a sensitive area long-term, but the evidence consistently supports that maintenance treatment of vulvar LS with low-frequency steroid application is both effective and safe when used as directed. The skin thinning (atrophy) associated with steroid overuse in other contexts is far less pronounced on vulvar skin, and undertreated LS causes more structural damage than appropriately managed steroid therapy does. The British Association of Dermatologists and ISSVD guidelines both explicitly support long-term maintenance treatment.
Advocacy in the Appointment Room Is Often Necessary — and Legitimate
Research consistently shows that women with vulvar conditions wait an average of several years between symptom onset and correct diagnosis, cycling through multiple clinicians who attribute symptoms to thrush, menopause, or anxiety. Asking directly — 'Could this be lichen sclerosus?' — is not an unreasonable self-advocacy move; it is the kind of specific question that changes the direction of a consultation. If a GP is unfamiliar with LS or unwilling to examine the vulvar skin, a referral to a vulval disease clinic, specialist dermatologist, or gynaecologist with an interest in vulval conditions is an appropriate and evidence-supported next step.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.